AASLD: Antiviral Likely Too Costly for Initial HCV Tx (CME/CE, with video)

SAN FRANCISCO (MedPage Today) — First-line treatment with the direct-acting antiviral agent telaprevir (Incivek) appeared unlikely to be cost-effective for hepatitis C virus infection in patients with the favorable CC IL28B polymorphism, according to a decision modeling analysis.

Post a Comment

Comments are closed.